Export 6 results:
Author Title [ Type(Desc)] Year
Filters: Author is Edupuganti, S  [Clear All Filters]
Journal Article
J. E. Ledgerwood, Bellamy, A. R., Belshe, R., Bernstein, D. I., Edupuganti, S., Patel, S. M., Renehan, P., Zajdowicz, T., Schwartz, R., Koup, R., Bailer, R. T., Yamshchikov, G. V., Enama, M. E., Sarwar, U., Larkin, B., Graham, B. S., and Team, andThe V. R. C. 70, DNA Priming for Seasonal Influenza Vaccine: a Phase 1b Double-Blind Randomized Clinical Trial, PLoS One, vol. 10, p. e0125914, 2015.
L. A. Jackson, Chen, W. H., Stapleton, J. T., Dekker, C. L., Wald, A., Brady, R. C., Edupuganti, S., Winokur, P., Mulligan, M. J., Keyserling, H. L., Kotloff, K. L., Rouphael, N., Noah, D. L., Hill, H., and Wolff, M. C., Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons, J Infect Dis, vol. 206, pp. 811-820, 2012.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., Creech, C. B., Hill, H., and Bellamy, A. R., Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine with MF59 Adjuvant: A Randomized Clinical Trial, JAMA, vol. 312, pp. 1420-1428, 2014.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. E., Rouphael, N. G., Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., Phase II Trial in Adults of Concurrent or Sequential 2009 Pandemic H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations, Vaccine, vol. 33, pp. 163-173, 2015.
W. A. Keitel, Jackson, L. A., Edupuganti, S., Winokur, P. L., Mulligan, M. J., Thornburg, N. J., Patel, S. M., Rouphael, N. G., Lai, L., Bangaru, S., McNeal, M. M., Bellamy, A. R., Hill, H. R., and Group, T. V. T. E. U. - H. 3Nv, Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons >/=18 Years Old, J Infect Dis, vol. 212, pp. 552-561, 2015.